

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Update on Noma: Systematic review on classification, outcomes and follow-up of patients undergoing reconstructive surgery after Noma disease

BMJ Open
bmjopen-2020-046303
Original research
30-Oct-2020
Speiser, Sophie; University College London, Division of Surgery and Interventional Science Langridge, Benjamin; University College London, Division of Surgery and Interventional Science; Royal Free London NHS Foundation Trust, Department of Plastic Surgery Birkl, Moira ; Karl Landsteiner University of Health Sciences Kubiena, Harald; Medical University of Vienna Rodgers, Will; Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Dental and Maxillofacial Surgery
Nutrition < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, SURGERY, Community child health < PAEDIATRICS, PLASTIC & RECONSTRUCTIVE SURGERY, Paediatric oral & maxillofacial surgery < PAEDIATRIC SURGERY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievont

Update on Noma: Systematic review on classification, outcomes and follow-up of patients undergoing reconstructive surgery after Noma disease

Authors

Miss Sophie Speiser^{a,b*}, M.D.

Division of Surgery & Interventional Science, University College London, London, United Kingdom

Email: sophie.speiser.19@ucl.ac.uk

Mr Benjamin Langridge^{a,b,c} MRCS Department of Plastic Surgery, Royal Free Hospital, London, United Kingdom Email: <u>b.langridge1@nhs.net</u>

Miss Moira Melina Birkl^d BSc Karl Landsteiner University of Health Sciences, Krems, Austria Email: 01248156@edu.kl.ac.at

Mr Harald Kubiena, M.D.

Private Practice Dr. Kubiena, Vienna, Austria

Email: office@drkubiena.at

Mr Will Rodgers MRCS

Great Ormond Street Hospital for Children NHS Foundation Trust | GOSH · Department of Dental and Maxillofacial Surgery, London, United Kingdom

Email: mr.w.rodgers@gmail.com

Affiliated departments and institutions:

^aDivision of Surgery & Interventional Science, University College London, London, United Kingdom

^bCharles Wolfson Center for Reconstructive Surgery, Royal Free Hospital, London, United Kingdom

^cDepartment of Plastic Surgery, Royal Free Hospital, London, United Kingdom

^dKarl Landsteiner University of Health Sciences, Krems, Austria

Corresponding Author: Sophie Speiser, M.D. Sophie.speiser.19@ucl.ac.uk

Phone: +447539539016

Permanent Address:

Division of Surgery & Interventional Science, University College London, London, United Kingdom

Royal Free Hospital, 9th Floor (East), 2QG, 10 Pond St, London NW3 2PS, United Kingdom

Word Count: 3688

ABSTRACT

Introduction: Noma is a significant yet neglected disease which affects some of the least developed countries in the world. The long-term benefit and safety of NOMA surgical reconstructive missions have recently been under scrutiny due to a perceived lack of measurable outcomes and appropriate follow-up. This study analyses and reports on classifications, outcome measurement tools, and follow-up for reconstructive surgery after Noma disease.

Methods: This systematic review was undertaken following PRISMA guidelines. The three medical databases Medline, EMBASE, and Web of Sciences were searched. All primary evidence on reconstructive surgery following Noma disease, reporting data on outcome after surgery, follow-up time and complications were included. Extracted data were aggregated to generate overall and population corrected mean outcomes and complication rates.

Results: Out of 1,393 identified records, 31 studies including 1,110 Noma patients were analysed. NOITULP and Montandon/WHO were the most commonly used classification systems. Mouth opening and complication rates were the two most often reported outcomes. Overall mean complication rate was 44%, reported by 24 studies. Postoperative mouth opening ("MO") was reported by 8 publications, of which, five reported long-term outcomes (> 12 months). Mean mouth improved by 20 mm when compared to mean population weighted preoperative MO (7 mm). At long-term follow-up MO decreased to 20 mm.

Conclusions: Studies reporting on neglected diseases in developing countries often lack methodological rigor. Surgeons should be mindful during patient examination by using a classification system that allows to compare pre- versus postoperative state of disease. Short-term mission surgery is a vital part of healthcare delivery to underdeveloped and poor regions. Future missions should aim at sustainable partnerships with local healthcare providers to ensure postoperative care and long-term patient-oriented follow-up. A shift towards a diagonal treatment delivery approach, whereby local surgeons and healthcare staff are educated and empowered, should be actively promoted.

PROSPERO registration number: CRD42020181931

Keywords: "Noma", "cancrum oris", "ulcerative necrotizing gingivitis", "facial reconstructive surgery", "global developmental surgery", "mission surgery", "classification", "outcomes", "complications", "trismus", "follow-up"

Strengths and limitations of this study

- Our statistical approach (qualitative synthesis) allowed us to compare different outcome measurement methods and give a recommendation for use of classification systems.
- Evidence on surgical outcome and follow-up after Noma disease is scarce and of low quality, which limits the strength of this systematic review.
- The majority of the studies included in this systematic review were case series, which are considered low-quality evidence and therefore limit the generalisability of the results.
- The publications we found represent only a small part of reconstructive surgical missions conducted for Noma disease, which could lead to potential bias of the results.

• Substantial heterogeneity between studies, including differences in outcome measurement and follow-up, limited our ability to draw clear conclusions about how safe reconstructive missions for Noma surgery are.

For peer teriew only

1 INTRODUCTION

Noma is a gangrenous ulcerating bacterial disease of multifactorial origin, mostly prevalent in sub-saharan Africa. Due to the high reported mortality rate of up to 85-90%, and its frequent occurrence in regions of extreme poverty, the WHO officially declared Noma a public health problem in 1994.(1) The global incidence is reported as 30,000-140,000 new cases per year.(1, 2) There are currently 210,000 Noma survivors worldwide, according to latest estimates.(2)

Most cases of Noma occur between the ages of 2-7 years old. Malnutrition, poor oral hygiene and poverty are known etiological factors leading to nutritionally acquired immune deficiency syndrome.(3, 4) Children with this syndrome present with lymphatic atrophy and impaired cellular immune responses, as accompanied by increased vulnerability to infections.(5) These preconditions lead to pathogen invasion through the gingival mucosa.(6, 7) After opportunistic infections take hold, progression to Noma disease occurs in several stages, starting with a simple gingivitis and ending in sequelae such as trismus, feeding difficulties and facial disfigurement.(1) Surgical reconstructive missions have become an established method to reduce the impact of diseases like Noma. The long-term patient benefit of these missions has come under scrutiny on multiple occasions, most recently by Hendriks et al. in 2019.(8)

The purpose of this systematic review is to analyse the currently used classification systems and compare methods of outcome assessment. In addition, the safety and patient-benefit of these procedures are analysed through comparison of complication rates and long-term outcomes.

2 METHODS

A comprehensive, structured literature search of published articles was conducted. This was designed by the authors S.S. and W.R. and performed in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).(9) Methods are described in more detail in the following sections.

2.1 Data sources

The literature search was performed using the electronic databases MEDLINE (PubMed), EMBASE and Web of Science. The keywords used in the search were selected from key papers and can be found in *Supplementary material- Part A*. Search strings 1 and 2 were combined using the Boolean term AND, then the limits were applied. In addition, a 'MeSH term' search was conducted, and the reference lists of included articles were reviewed for any additional articles.

2.2 Study eligibility criteria

Articles were eligible for inclusion if they provided primary empirical evidence of patient outcomes after Noma surgery. The full inclusion and exclusion criteria are detailed in *Supplementary material- Part A*. Study selection was independently assessed by 2 reviewers (S.S. and M.B.).

2.3 Data extraction and analysis

Articles were systematically analysed and data extracted using a structured data collection sheet. This data collection template was pilot tested on two selected articles, before being used to assess all included articles. Data extracted included patient demographics (gender, age, comorbidities), and any outcome measurement tools used.

2.4 Methodological quality and assessment of bias

Included studies were assigned a level of evidence based on the Oxford Centre for Evidence Based Medicine.(10) In Addition, studies were rated for methodological quality using the methodological index for non-randomized studies (MINORS) criteria, both tools are explained in detail in *Supplementary material- Part B.*(11)

2.5 Statistical analysis

Data were analysed using IBM SPSS statistics version 24. Descriptive statistics were performed where possible to allow for narrative synthesis. Weighted population mean outcomes were calculated for outcomes of interest.

Meaningful meta-analysis was not possible due to Heterogenous study design and outcome reporting. Averages were represented as a mean and range for normally distributed data and median with IQR for non-normally disributed data. Outcomes were weighted for size of study population, as some studies had larger population sizes and therefore higher weighting.

2.6 Patient and public involvement

Neither patients nor the public were involved in this research.

to beet eview only

3 RESULTS

3.1 Selection of Studies

In total, the systematic literature search identified 1,393 records. In addition, 7 records were identified through bibliography review. After excluding duplicates; titles and abstracts of 1,113 articles were screened, with 1,049 being excluded. 64 studies were fully assessed for eligibility according to the criteria previously established. 33 articles were excluded, 23 of which did not report any outcomes of surgery and 6 had duplicate study populations.

Data were extracted from the 31 included articles. Data extraction was pilot tested on two studies and then performed by two independent reviewers (M.B. and S.S), using a data extraction sheet designed a priori. The selection process was performed according to the PRISMA flow chart, as seen in *Supplementary material- Part C*.

3.2 Details of the Studies

In total, data were available for articles published in the period 1983-2020. The methodology, diagnostic approach and surgical treatment varied significantly between the studies. In total, published data for 1,244 patients from 31 studies were analysed, out of which 1,110 patients had reconstructive surgery for Noma disease. In cases of mixed disease populations, estimates were made based on population overall descriptive statistics, dividing the total outcome by Noma population proportions. Patient populations ranged from 2 to 148 patients, with an average of 36 Noma patients enrolled per study. 29 studies were case series, four of them were prospective,(12-15) 25 were retrospective. Two publications had at least two cohorts,(16-18) two were retrospective cohort studies, and one was a prospectively designed cohort study.(17)

The overall quality of the studies was low. Three publications(16-19) were graded with an evidence Level III according to the Oxford CEBM. The remaining 28 studies were retrospective case series graded as Level IV. The MINORS criteria(11) were used to rate quality of methods of the included studies. The overall MINORS scores ranged from 1 to 8 points, as seen in *Supplementary material- Part D*. Proportional scores were calculated as a percentage of the maximum score of 8 for case series and 12 for cohort studies. Scores ranged from 13-75% of the maximum amount of points. The quality level was generally low: more than half of the studies did not even reach 50% of the ideal outcome.

3.3 Patient Characteristics

Median age for operation was 17 years, reported by 23 studies and ranged from 4.5-35.7 years. 584 (53%) female and 424 (38%) male patients were included. For 102 (9%) patients the gender was not known. The median percentage of female population was 56% (43-65%).

6 studies had a malnutrition rate ranging from 25-100%, with an average of over 56% (median (IQR)) (53.5 (25-81%)) of patients being severely malnourished upon study inclusion. No specific details were given on how malnutrition was measured in the included studies. HIV status was stated by six studies, of which 5 pre-screened patients, and only included HIV seronegative patients.(16, 20-23)

3.4 Classification Systems

The two most common classification systems were the NOITULP, introduced by Marck et al.(15) and the Montandon/WHO, first described by Montandon et al.(24) in 1991, as seen in *Figure 1*.

The NOITULP approach uses the letters N-"nose", O-"outer cheek", I-"inner cheek", T-"trismus", U-"upper lip", L-"lower lip" and P-"particularities" to describe the anatomical subunits affected and gives them a rating from 0-4, depending on the severity of the defect. Nose, cheek, lip and maxilla/mandible involvement were the most commonly mentioned fields, as seen in *Figure 2*.

Six of the included studies used the Montandon classification to rate disease severity. (14, 25-29) Type I represents a localized lip, commissure, or cheek defect that normally can be lined by local tissues and covered with a single flap. Type II includes an upper lip and nose amputation. Type III involves a lower lip and mandible amputation, and Type IV marks large defects involving the lips, cheek, palate, maxillary bone, orbital floor and other entities.

Montandon classification data was available on 376 patients. Out of these, 147 patients (39%) were classified as Montandon Type I, 53 (14%) presented as Montandon Type II, 15 (4%) were rated as Montandon Type III, and 161 patients (43%) had Montandon Type IV.

Trismus as a complication of Noma disease was stated by 26 studies. On average, 59.6% (39.2-95.9) of the patient population per study presented with trismus. Trismus was further subdivided into T1-T4 in 257 patients, as seen in *Figure 3*.

The mean preoperative mouth opening was calculated only for the 257 patients that further divided the trismus classifications into T1-T4. the population weight corrected mean was used as a proxy for comparison where average values were not provided by the original publication. Population weight-corrected median preoperative mouth opening was 7 mm (5-15 mm).

3.5 Surgical Interventions

Hospital duration ranged from 2-140 days, with a mean of 5.5 days. 255 patients were treated by local surgeons in six studies (23%) and 855 patients were operated on by mission surgeons in 20 of the studies (77%).

3.6 Outcomes and Follow-up Time

Objective outcomes were further subdivided into four categories (trismus (MO) and complication rate.

Complication rate as outcome

In total, 204 complications were reported in 24 studies. Median complication rate was 24% (13-53%) per study and ranged between 1%-200%. The 200% complication rate was seen in a study by Hartman et al.(30), where six complications occurred in three patients.

 Table 1- Most common short-term complications

Complication	Rate n (%)
Infection	37 (18)
Partial flap necrosis	26 (13)
Total flap loss and necrosis	20 (10)
Bleeding/hematoma	12 (6)
Donor site dehiscence	12 (6)
Recurrent fistula	11 (5)

Systematic review on Noma surgery

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1	
2	
2 3 4	
4	
5	
6 7 8 9 10	
7	
8	
9	
10	
11	
12	
13	
14	
11 12 13 14 15	
16	
17 18	
18	
19	
20	
21	
22	
19 20 21 22 23 24 25	
24	
25	
26 27	
27	
27 28 29	
29 30	
30 21	
31 32	
32 33	
33 34	
35	
35 36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	

Others

20 (10)

The most common short-term complications can be seen in *Table 1*. Long term complications over 12 months were only stated in two publications. Bisseling et al.(31) reported on long-term results of 36 patients undergoing trismus release with mean follow up of 43 months (12-78). 22% of these patients experienced difficulties eating and 14% had difficulties with speaking. Honeyman et al.(16) reported 15 long term complications: chronic fistula (n=6) chronic infection (n=3) , chronic pain (n=2), keloid scarring (n=2), wound breakdown (n=1), exposed metal work (n=1). In total, 30% of the population (21 patients) experienced long-term complications.

Trismus (mouth opening) as outcome

Trismus release, stated as a postoperative mouth opening (MO) of >3 cm, was achieved in 189 out of 349 patients, reported by 13 publications. Average rate of successful trismus release was 53%. Three publications reported a 100% postoperative trismus release rate.(23, 29, 32) Persisting trismus after surgery was reported in eight publications and was present in 83 out of 286 cases (29%).

Mean postoperative MO was reported only by 8 publications and ranged from 23-35 mm. Population- weighted mean postoperative MO was 27 mm.(24-27)

Mean MO at long-term follow up was available for 5 publications and ranged from 10.3-35.0 mm. Population weighted mean mouth opening at long-term follow up was 20 mm (median (IQR)) (19 (15-21)). *Figure 4* shows population weighted mean mouth opening preoperatively, postoperatively and at long-term follow-up.

Subjective Outcome Measures

Subjective postoperative outcomes included cosmetic/aesthetic improvement, reported by 3 studies, and overall improvement (aesthetic and functional), reported by 8 publications. No further details on how improvement was measured was given by the publishers. No information on if this was patient-measured or observer-measured was stated.

Median length of follow up was reported by only 8 publications, which was 24 months (12.7-45). and ranged from 31 days to 324 months (27 years).(28) Death was reported in 23 cases (2%).(25, 33) Nath and Jovic reported on 81 patients treated on Noma which were HIV positive in Zambia, out of which 11 patients died during initial medical treatment for infection, and 12 (13.6%) died following minor surgery. No further information on comorbidities or health status of these children was provided. In the study published by Chidzonga and Mahova, all patients were HIV seropositive. One patient developed severe pneumonia and died before reconstructive surgery, another patient died one month after admission, no further detail on the cause of death was given. A third patient died one month after initial soft tissue debridement and sequestrectomy. All patients showed severe facial tissue loss and dentoalveolar necrosis.

Long-term follow-up, which was defined as longer than 12 months, was reported by only six publications (263 patients in total), and mean loss to follow-up was 56%.

DISCUSSION

Noma affects mostly children in the poorest and least developed regions of the world. It causes facial disfigurement and can lead to functional impariment such as loss of oral competency including salivary leakage and trismus. This is the first systematic review specifically analysing the classification, complications and long-term outcomes of Noma surgery, both in local and in mission surgery settings.

Thirty-one studies met the inclusion criteria, with a total of 1,110 patients included which had undergone reconstructive surgery for Noma disease. The overall methodological quality of the studies, rated by the MINORS criteria, was poor and reflects similar outcomes of the systematic review on trismus conducted by Bouman et al. in 2016 (34). Over half the studies we included reached 50% or less in the MINORS score. Non-randomized studies with high quality are usually rated 83% and higher, according to Slim et al..(11) Out of the 31 studies included, four of them were prospective, and two of them cohort studies. Challenges of performing rigorous studies in the developing world include limited resources and the short time frame of two to three weeks, which the surgeons typically spend on surgical missions. This can be improved by promoting a system where high-quality research can be provided by local staff with the support of plastic surgeons from more developed countries, advocating an academically profitable partnership, sustainable throughout the year.

Classification systems have been proposed by several authors, the two most commonly used were NOITULP, introduced by Marck et al.(15) in 1998 and Montandon/WHO, first described by Montandon et al.(24) in 1991.

Montandon et al.(24) based their system on two publications by Cariou(35) in 1986 and Raynaud et al.(36) in 1978. The approach Montandon suggested was rating the defect based upon its severity, taking into account the surgical strategy needed to successfully reconstruct the face.

Marck et al. found that the previously described classifications lacked in brevity as in conciseness and were not quantifiable in the way NOITULP is.(15) NOITULP covers anatomical subunits and severity of defect, not previously taken into account by any system.

While the Montandon classification has been validated by the WHO in 1994,(1) Noma surgeons are still using both classification systems in parallel. While the Montandon classification is simple and easy to comprehend and apply, it might not fully grasp the disease severity, and it misses one important disease characteristic: trismus. However, the NOITULP classification has a more holistic approach and is more complex in its entirety. The question to be asked is, what do the surgeons want to achieve by using the tool and how can we compare the pre- to postoperative state of the patients and ideally use it as a control system for disease relapse or progression. In addition, the system must be comprehensible by the surgeon using it, which ultimately shall be a surgeon within the local healthcare system. One suggestion might be to distinguish between a role for a more complex classification to be used predominantly in the research setting, while the other could have a more direct clinical role. In addition, the role of patient reported outcome measures (PROMs) should be explored with Noma patients. If the patient does not feel that they have benefited from the operation, then it is entirely irrelevant how the surgeon rates the postoperative outcome. Validated questionnaires are one possible way to report patient-reported outcomes.(37)

Out of the 31 studies analysed, in only six studies were the operations undertaken by a local surgeon. The majority of operations were undertaken by mission surgeons travelling to the region. This vertical approach to healthcare includes short missions of two to three weeks. Unfortunately, these missions are typically characterised by a higher risk of poor follow up.

They are also often fail to provide a holistic approach to the patient's ongoing treatment after surgery, especially when compared against clinics that include permanent local surgeons and healthcare staff.(8) This was well reflected in the outcomes and follow up seen in the 31 publications we analysed. Outcome measurements were inconsistent, and follow-up was incomplete in the majority of publications (81%).

While postoperative complication rates were available for the majority of studies (77%), long term complications were only reported by two publications. Bisseling et al.(31) reported that 22% of patients experienced loss of oral competency and 14% had difficulties with speaking. Honeyman et al. reported a 30% long-term complication rate. These high long-term complication rates, including severe complications such as loss of oral competency, make the long-term benefit of these short-term missions questionable, as stated previously by Hendriks et al..(8) Reasons for the high complication rates could be lack of postoperative physiotherapy and/or regular follow-up visits. It is therefore important that any surgical missions develop links with the local healthcare system in order to ensure that complications can be managed effectively and to provide training where required for local healthcare workers.

Postoperative mouth opening as an outcome of trismus release was reported by eight studies, and long-term follow up data were available for five publications. Underreporting of outcomes and limited follow-up suggest a potential risk of reporting bias, leading to overestimation of the beneficial impact of these missions. Nevertheless, population-corrected mean postoperative mouth opening at long-term follow up (>12 months) was 20 mm, which represents a 13 mm increase compared to the preoperative mean. It is worth mentioning at this point, that there is broad range of ages for the patients included in this review. Whether a 20 mm increase in mouth opening is of any relevance changes based on age as an adult mouth is larger than a young child's mouth. Unfortunately, no further details were given on the ages of the patients measured at long-term follow up.

Bisseling et al.(31) followed-up patients treated in the Noma Childrens Hospital in Sokoto, Nigeria. In this mission hospital, in the majority of patients, contact is lost entirely after discharge and long-term outcome is not known. Therefore, they tried to revisit the patients in their home communities to retrieve patient outcome data. Out of 130 patients documented, only 36 patients were found and included into the study, representing a greater than 70% loss to follow-up rate. Similarly high losses were reported by Pittet et al. (79%) and Vinzenz et al. (38) (78%) and slightly less by Dammer et al. (50%), reflecting the challenges of providing adequate ongoing care in the developing world. Reasons for high losses to follow-up could be inconsistency in local healthcare provision and lack of infrastructure and long distances that have to be overcome by the parents and the child to reach the local clinics.

Ruegg et al. (27) lost only 21% of their patients to follow-up, with their patients being treated in Switzerland and repatriated following discharge from hospital. They were followed up by the local healthcare workers of the Swiss charity Sentinelles. They implemented a local complication report and follow up system, working together with physiotherapists and ensuring local healthcare support and regular controls throughout the year. Whereas it is often not feasible to fly Noma patients to Europe for treatment, their strategy of consistent local care and staff to oversee the postoperative healing process on site helped them stay connected with their patients and ensured their wellbeing after reintegration.

Transition from a vertical approach, where short-term missions are performed, but no activities throughout the year are supported, to a more diagonal strategy, used for mission surgery in underdeveloped countries, has previously been suggested by Patel et al. (39). In this model, which was originally developed for cleft lip and palate patients, they combine short-term missions with ongoing measures such as the support of local staff with residency

programs, financial support, research training, academic partnerships and equipment for surgery.

This sustainable treatment strategy was further promoted by Hendriks et al. (8) in 2019. Working together with local staff and implementing a mutually beneficial partnership helps ensure a holistic approach towards healthcare provision and management in underdeveloped countries.

Advantages of this system include development of a long-term presence in the respective countries with the ultimate goal of building local surgical capacity and treatment independence in a supported setting. Visiting surgeons benefit from experience in global healthcare delivery and have the chance to transfer their knowledge to local surgeons, who gain surgical skills and experience. In addition, other local healthcare workers can be trained including nutritionists, physiotherapists and speech therapists, to support the patients in the perioperative settings (39).

Data on how far this has been implemented in hospitals treating Noma patients is scarce. However, given the low long-term follow-up rate and incomplete reporting of outcomes in studies published up to date, implementation of this model is likely limited in Noma patients.

The systematic review conducted demonstrates the current most common classification systems used, outcomes and follow-up for reconstructive surgery following Noma disease to-date. Consistency in classifying and following up on patients imposes a challenge for neglected diseases in developing countries, no less so for Noma. When classifying disease severity of Noma patients, surgeons should aim to achieve comparability of the pre- versus postoperative and long-term status by using a classification system that allows documentation of affected anatomical subunits, as well as to note trismus severity at every point in follow-up.

Tools for measuring surgical outcomes in Noma patients are scarce and need further research and validation. Complication rates and mouth opening were the two most commonly reported outcomes. In general, reported outcomes were often inconsistent and of low quality, as was evidence of follow-up data. Short-term mission surgery is a vital part of healthcare delivery to underdeveloped regions. Future missions should focus on fostering cooperation and forming partnerships with local organisations to ensure postoperative care and long-term patient-oriented follow-up. A shift towards a diagonal treatment delivery approach where local surgeons and healthcare staff are educated and supported should be actively promoted.

Abbreviations:

 CEBM- Center of evidence-based medicine

IQR- Interquartile range

MINORS- Methodological index for non-randomized studies

MO- Mouth opening

NOITULP- anagram as classification system for Noma disease

PRISMA- Preferred reporting items for systematic reviews and meta-analyses

WHO- World Health Organization

Author Contributions:

Miss Moira Melina Birkl BSc.: Second reviewer, design of study, data interpretation, manuscript preparation

Mr Benjamin Langridge MRCS: Third reviewer, design of study, data interpretation, manuscript preparation

Mr Harald Kubiena, M.D.: design of study, manuscript preparation

Mr Will Rodgers MRCS: design of study, data interpretation, manuscript preparation

Funding: This work has not previously been presented in any format. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The article processing charge was kindly paid for by University College London as part of their Open Access policy.

review only

Data sharing statement: If additional data is requested please contact

sophie.speiser.19@ucl.ac.uk .

Competing interests: None declared.

REFERENCES

 1. Bourgeois DM, Leclercq MH. The World Health Organization initiative on noma. Oral Dis. 1999;5(2):172-4.

2. Srour ML, Marck K, Baratti-Mayer D. Noma: Overview of a Neglected Disease and Human Rights Violation. Am J Trop Med Hyg. 2017;96(2):268-74.

3. Chandra RK. 1990 McCollum Award lecture. Nutrition and immunity: lessons from the past and new insights into the future. Am J Clin Nutr. 1991;53(5):1087-101.

4. Leila Srour M, Marck KW, Baratti-Mayer D. Noma: neglected, forgotten and a human rights issue. Int Health. 2015;7(3):149-50.

5. Beisel WR. Nutrition and Immune Function: Overview. The Journal of Nutrition. 1996;126(suppl_10):2611S-5S.

6. Baratti-Mayer D, Gayet-Ageron A, Hugonnet S, Francois P, Pittet-Cuenod B, Huyghe A, et al. Risk factors for noma disease: a 6-year, prospective, matched case-control study in Niger. Lancet Glob Health. 2013;1(2):e87-e96.

7. Baratti-Mayer D, Pittet B, Montandon D, Bolivar I, Bornand JE, Hugonnet S, et al. Noma: an "infectious" disease of unknown aetiology. Lancet Infect Dis. 2003;3(7):419-31.

8. Hendriks TCC, Botman M, Rahmee CNS, Ket JCF, Mullender MG, Gerretsen B, et al. Impact of short-term reconstructive surgical missions: a systematic review. BMJ Global Health. 2019;4(2):e001176.

9. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.

10. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plastic and reconstructive surgery. 2011;128(1):305-10.

11. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712-6.

12. Bouman MA, Marck KW, Griep JE, Marck RE, Huijing MA, Werker PM. Early outcome of noma surgery. J Plast Reconstr Aesthet Surg. 2010;63(12):2052-6.

13. Dammer R, Dunzl B, Kuhnel T. [Therapy of bony and fibrous contractures and buccal defects after noma using the temporalis muscle flap]. Mund Kiefer Gesichtschir. 2005;9(4):225-32.

14. Kuhnel TS, Dammer R, Dunzl B, Beule AG, Strutz J. New split scar cheek flap in reconstruction of noma sequelae. Br J Plast Surg. 2003;56(6):528-33.

3

4 5

6

7

8 9

10

11 12

13

14

15 16

17

18

19 20

21

22

23 24

25

26

27

28 29

30

31 32

33

34

35 36

37

38

39 40

41

42

43 44

45

46

47 48

49

50

51 52

53

54

55 56

57

58

59 60 15. Marck KW, De Bruijn HP, Schmid F, Meixner J, Van Wijhe M, Van Poppelen RHM. Noma: The Sokoto approach. European Journal of Plastic Surgery. 1998;21(6):277-80. Honeyman C, Patel V, Yonis E, Fell M, Demissie Y, Eshete M, et al. 16. Long-term outcomes associated with short-term surgical missions treating complex head and neck disfigurement in Ethiopia: A retrospective cohort study. Journal of Plastic, Reconstructive and Aesthetic Surgery. 2020. 17. Huijing MA, Marck KW, Combes J, Mizen KD, Fourie L, Demisse Y, et al. Facial reconstruction in the developing world: a complicated matter. Br J Oral Maxillofac Surg. 2011;49(4):292-6. 18. Marck R, Huijing M, Vest D, Eshete M, Marck K, McGurk M. Early outcome of facial reconstructive surgery abroad: a comparative study. European journal of plastic surgery. 2010;33(4):193-7. Oluwasanmi JO, Lagundove SB, Akinyemi OO. Ankylosis of the 19. mandible from cancrum oris. Plast Reconstr Surg. 1976;57(3):342-50. Giessler GA, Borsche A, Lim PK, Schmidt AB, Cornelius CP. First 20 experiences with simultaneous skeletal and soft tissue reconstruction of nomarelated facial defects. J Reconstr Microsurg. 2012;28(2):85-94. Giessler GA, Cornelius CP, Suominen S, Borsche A, Fieger AJ, Schmidt 21. AB, et al. Primary and secondary procedures in functional and aesthetic reconstruction of noma-associated complex central facial defects. Plast Reconstr Surg. 2007;120(1):134-43. Giessler GA, Fieger A, Cornelius CP, Schmidt AB. Microsurgical 22. reconstruction of noma-related facial defects with folded free flaps: an overview of 31 cases. Ann Plast Surg. 2005;55(2):132-8. Giessler GA, Schmidt AB. Noma: experiences with a microvascular 23. under West African conditions. Plast approach Reconstr Surg. 2003;112(4):947-54; discussion 55-6. Montandon D, Lehmann C, Chami N. The surgical treatment of noma. 24. Plast Reconstr Surg. 1991;87(1):76-86. Chidzonga MM, Mahomva L. Noma (cancrum oris) in human 25. immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV and AIDS): clinical experience in Zimbabwe. J Oral Maxillofac Surg. 2008;66(3):475-85. 26. Pittet B, Jaquinet A, Montandon D. Clinical experience in the treatment of noma sequelae. J Craniofac Surg. 2001;12(3):273-83. Ruegg EM, Baratti-Mayer D, Jaquinet A, Montandon D, Pittet-Cuenod 27. B. The surgical management of extra-articular ankylosis in noma patients. International Journal of Oral & Maxillofacial Surgery. 2018;47(12):1527-33. 28. Ruegg EM, Gniadek P, Modarressi A, Baratti-Mayer D, Pittet-Cuenod B. Facial bone reconstruction with prefabricated vascularized calvarium flaps in children and young adults: Advantages and long-term results. Journal of Cranio-Maxillofacial Surgery. 2016;44(12):1880-8.

29. Simon F, Wolfe SA, Guichard B, Bertolus C, Khonsari RH. Paul Tessier facial reconstruction in 1970 Iran, a series of post-noma defects. J Craniomaxillofac Surg. 2015;43(4):503-9.

30. Hartman EHM, Van Damme PA, Sauter H, Suominen SHH. The use of the pedicled supraclavicular flap in noma reconstructive surgery. Journal of Plastic, Reconstructive and Aesthetic Surgery. 2006;59(4):337-42.

31. Bisseling P, Bruhn J, Erdsach T, Ettema AM, Sautter R, Berge SJ. Longterm results of trismus release in noma patients. Int J Oral Maxillofac Surg. 2010;39(9):873-7.

32. Holle J. Lockjaw treatment after noma in the third world. J Craniofac Surg. 2009;20 Suppl 2:1910-2.

33. Nath S, Jovic G. Cancrum oris: management, incidence, and implications of human immunodeficiency virus in Zambia. Plast Reconstr Surg. 1998;102(2):350-7.

34. Bouman MA, Dijkstra PU, Reintsema H, Roodenburg JL, Werker PM. Surgery for extra-articular trismus: a systematic review. Br J Oral Maxillofac Surg. 2016;54(3):253-9.

35. Cariou J, editor Le noma dans la corne de l'Afrique: approche thérapeutique. Ann Chir Plast Esthet; 1986.

36. Reynaud J, Garand G, Ployet MJ, Robier A. Du noma au syndrome de Silvermann: une pathogÈnie ‡ discuter. Ann Chir Plast. 1978;23(4):227-30.

37. Weldring T, Smith SMS. Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs). Health Serv Insights. 2013;6:61-8.

38. Vinzenz K, Holle J, Wuringer E. Reconstruction of the maxilla with prefabricated scapular flaps in noma patients. Plast Reconstr Surg. 2008;121(6):1964-73.

39. Patel PB, Hoyler M, Maine R, Hughes CD, Hagander L, Meara JG. An opportunity for diagonal development in global surgery: cleft lip and palate care in resource-limited settings. Plast Surg Int. 2012;2012:892437-.

FIGURES AND TABLES

Table 1- Most common short-term complications 6


Figure 1- Noma classification systems used 6

Figure 2- Subunits used for disease classification 6

Figure 3- Trismus severity reported preoperatively 6


Figure 4- Mouth opening at preoperative, postoperative and long-term follow-up points 7

Page 21 of 33 Noma classific ation systems used




Subunits used for Malerease classification

Page 22 of 33




Page 23 of 33

Trismers Severity



Mean Mowthe Opening

Page 24 of 33



SUPPLEMENTARY MATERIAL

PART A- SEARCH STRATEGY

Keywords

Search strategy for Embase.com (15.04.2020)

/exp = EMtree keyword with explosion

.tw = The Textword field in EMBASE includes Title (TI) and Abstract (AB).

Number	Search terms	Results
#1	exp plastic surgery/ OR exp surgeon/ OR exp plastic surgeon/ OR exp esthetic surgery/ OR	8557452
	exp skin transplantation/ OR exp microsurgery/ OR exp tissue flap/ OR exp Z plasty/ OR exp	
	surgical flaps/ OR exp reconstructive surgery/ OR exp face surgery/ OR exp maxillofacial	
	surgery/ OR exp oral surgery/ OR skin graft*.tw. OR full thickness graft*.tw. OR SSG.tw. or	
	FTG.tw OR axial flap*.tw. OR pedicled flap*.tw. OR surgical flap*.tw. OR contracture	
	release*.tw. OR exp free tissue graft/ OR free flap*.tw. OR regional flap*.tw. OR exp skin	
	flap/ OR local flap*.tw. OR surger*.tw. OR surgical*.tw. OR operation*.tw. OR	
	operative*.tw. OR incisi*.tw. OR excisi*.tw. OR management*.tw. OR treatment.tw	
#2	Exp Vincent stomatitis/ OR acute necrotizing ulcerative gingivitis.tw OR acute necrotising	1401
	ulcerative gingivitis.tw OR acute ulcerative gintivitis.tw OR Noma.tw OR cancrum oris.tw	
#3	#1 AND #2	639
Limits: Pul	blication prior to final search, April 15th, 2020	

Search strategy for MEDLINE (PubMed) (15.04.2020)

/exp = MEDLINE keyword with explosion/ Mesh terms .tw = The Textword field in MEDLINE includes Title (TI) and Abstract (AB).

Number	Search terms			Results
#1	exp Reconstructiv	e Surgical Procedures/ OR exp	o Surgery, Plastic/ OR exp Tissue	8167413
	Transplantation/	OR exp Surgical Flaps/	OR exp Skin Transplantation/ ORexp Free	
	Tissue Flaps/	OR exp Microsurgery/ OR e	xp Surgery, Oral/ OR exp Surgical	
	Procedures, Opera	tive/ OR exp "Oral and Maxil	lofacial Surgeons"/ OR exp Surgeons/ OR	
	skin graft*.tw.	OR full thickness graft*.tw.	OR SSG.tw. OR FTG.tw. OR axial flap*.tw.	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	OR pedicle flap*.tw. OR pedicled flap*.tw. OR surgical flap*.tw. OR contracture release*.tw. OR free flap*.tw. OR regional flap*.tw. OR local flap*.tw. OR surger*.tw. OR surgical*.tw.	
	OR operation*.tw. OR operative*.tw. OR incisi*.tw. OR excisi*.tw. OR management*.tw.	
	OR treatment*.tw	
#2	exp Noma/ OR cancrum oris.tw. OR exp Gingivitis, Necrotizing Ulcerative/ OR acute	1664
	necrotizing ulcerative gingivitis.tw. OR acute necrotising ulcerative gingivitis.tw.	
#3	#1 AND #2	568
Limits:	Publication prior to final search, April 15th, 2020	
Limits:	Publication prior to final search, April 15th, 2020	

Search strategy for Clarivate Analytics/Web of Science (15.04.2020)

TOPIC = words in title, abstract or keywords ndexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years

Number	Search terms	Results
#1	TS= (surger* OR surgical* OR surgeon* OR operation* OR operative* OR incisi* OR	9,621,445
	extracti* OR excisi* OR management* OR treatment*)	
#2	TS= (reconstructi* OR cosmetic* OR esthetic* OR aesthetic* OR plastic OR corrective* OR	8,095,337
	oral* or *maxillofacial* OR facial OR face* OR "head and neck" OR flap* OR skin* or	
	micro*)	
	4	
#3	TS= (Noma OR "cancrum oris" OR "necrotizing ulcerative gingivitis" OR "acute necrotizing	3,515
	ulcerative gingivitis" OR "acute necrotising ulcerative gingivitis")	
#4	#2 AND #1	1,821,209
#5	#4 AND #3	186
Limits: Pu	blication prior to final search, April 15th, 2020	

Inclusion/exclusion criteria

Inclusion Criteria 1. Original publications 2. Human subjects 3. Case Series, Retrospective Data Analyses, Clinical Trials, Controlled Clinical Trials, Prospective Studies

2	
3	
4	
5	
6	
7	
/	
8	
9	
10	
11	
12	
13 14	
14	
15	
16	
16 17	
17	
18	
19	
20	
21	
22	
23	
24	
24 25	
25	
26	
27	
28	
29	
30	
31	
32	
33	
22	
34	
35	
36 37	
37	
38	
39	
40	
41	
42	
42 43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
00	

Exc	lusio	n Criteria
	1.	Publication type does not match inclusion criteria (Review articles, Mixed methodology studies without
		subgroup data, Animal studies, Conference Articles)
	2.	Conditions other than Noma, Cancrum Oris, or Necrotizing Ulcerative Stomatitis not related to Noma
	3.	The paper is about conditions located at sites other than the Maxillofacial and Head and Neck region
	4.	The paper is not about treatment
	5.	The paper is not about a surgical intervention (but included if terms such as reconstruction or rehabilitation,

or flap or graft, are mentioned).

The paper is about prevention rather than treatment of Noma 6.

Systematic review on Noma surgery For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

PART B- MINORS CRITERIA

MINORS criteria

Level of Evidence	Types of Studies
Ι	SR (with homogeneity) of RCTs, Individual RCT (with narrow Confidence Interval),
Π	SR (with homogeneity) of cohort studies, Individual cohort study (including low quality RCT; e.g., <80% follow-up), "Outcomes" Research; Ecological studie
III	SR (with homogeneity*) of case-control studies, Individual Case-Control Study
IV	Case-series (and poor-quality cohort and case-control studies)
V	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"

A clearly stated aim: the question addressed should be precise and relevant in the light of available literature Inclusion of consecutive patients: all patients potentially fit for inclusion (satisfying the criteria for inclusion) have been included in the study during the study period (no exclusion or details about the reasons for exclusion) Prospective collection of data: data were collected according to a protocol established before the beginning of the study Endpoints appropriate to the aim of the study: unambiguous explanation of the criteria used to evaluate the main outcome which should be in accordance with the question addressed by the study. Also, the endpoints should be assessed on an intention-to-treat basis.

5. Unbiased assessment of the study endpoint: blind evaluation of objective endpoints and double-blind evaluation of subjective endpoints. Otherwise the reasons for not blinding should be stated

6. Follow-up period appropriate to the aim of the study: the follow-up should be sufficiently long to allow the assessment of the main endpoint and possible adverse events

7. Loss to follow up less than 5%: all patients should be included in the follow up. Otherwise, the proportion lost to follow up should not exceed the proportion experiencing the major endpoint

8. Prospective calculation of the study size: information of the size of detectable difference of interest with a calculation of 95% confidence interval, according to the expected incidence of the outcome event, and information about the level for statistical significance and estimates of power when comparing the outcomes

Additional criteria in the case of comparative study

9. An adequate control group: having a gold standard diagnostic test or therapeutic intervention recognized as the optimal intervention according to the available published data


10. Contemporary groups: control and studied group should be managed during the same time period (no historical comparison)

11. Baseline equivalence of groups: the groups should be similar regarding the criteria other than the studied endpoints. Absence of confounding factors that could bias the interpretation of the results

12. Adequate statistical analyses: whether the statistics were in accordance with the type of study with calculation of confidence intervals or relative risk

tor peer teriew only

PART C- PRISMA FLOW CHART



PART D- MINORS CRITERIA FOR INCLUDED STUDIES

Type case series (RS) case series (PS) case series (RS) case series (RS)	Level of Evidence 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 1 August 2021 Downloaded from but 2021 Downl
case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (RS)	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
case series (RS) case series (PS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (RS) case series (RS)	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 1 12 2021 Deweiler der Uner Hereit
case series (RS) case series (PS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (RS) case series (RS)	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 3 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1 0 2021 Dewalded from the device of the second sec
case series (RS) case series (PS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (PS) case series (RS)	4 4 4 4 4 4 4 4 4 4 4 4 4 4 3 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
case series (RS) case series (PS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (PS) case series (RS)	4 4 4 4 4 4 4 4 4 4 4 4 4 3 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
case series (PS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (PS) case series (RS)	4 4 4 4 4 4 4 4 4 4 4 4 3 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (PS) case series (RS)	4 4 4 4 4 4 4 4 4 4 3 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (RS)	4 4 4 4 4 4 4 4 3 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{ccccccc} 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 &$	
case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (PS) case series (RS)	4 4 4 4 4 4 4 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccc} 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 1 & 1 & 0 \\ 1 & 1 & 1 \\ 1 & 1 & 1 \end{array}$	
case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (RS)	4 4 4 4 4 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{ccccc} 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \\ 1 & 1 & 0 \\ 1 & 1 & 1 \\ 1 & 1 & 1 \end{array}$	
case series (RS) case series (RS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (RS)	4 4 4 4 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccc} 0 & 0 & 0 \\ 0 & 0 & 0 \\ 1 & 1 & 0 \\ 1 & 1 & 1 \\ 1 & 1 & 1 \end{array}$	
case series (RS) case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (RS)	4 4 4 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccc} 0 & 0 & 0 \\ 1 & 1 & 0 \\ 1 & 1 & 1 \\ 1 & 1 & 1 \end{array}$	
case series (RS) case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (PS) case series (RS)	4 4 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
case series (RS) cohort study (RS) cohort study (PS) case series (PS) case series (RS)	4 4 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
cohort study (RS) cohort study (PS) case series (PS) case series (PS) case series (RS)	4 3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1 1 0
cohort study (PS) case series (PS) case series (PS) case series (RS)	3 3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1 1 0 0 1 1	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1 I <u>9</u>
case series (PS) case series (PS) case series (RS)	3 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	1 1 0 0 1 1	0 1 0	1 1 0 😨
case series (PS) case series (RS)	4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$			1 0 Og
case series (RS)	4 4	0 1 0 0 0 0 0	1 1 0 0 0 0		1 1 Og
	4				0 0 0
case series (RS)					
	4				0 0 0
case series (RS)	4				
case series (RS)				0 0 1	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
· (D.C)	4		1 1 0 0 1 1	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
case series (RS)	4	1 1 1 1 0 0 0	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
case series (RS)	4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 0 66 1 1 69 0 1 69 1 1 6 0 0 61 1 1 23 0 0 23
case series (RS) case series (RS)	4 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 0 6 7 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8
case series (RS) case series (RS) case series (RS)	4 4 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 0 6 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7
case series (RS) case series (RS) case series (RS) case series (RS)	4 4 4 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
case series (RS) case series (RS) case series (RS)	4 4 4 4 4 4 4	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 1 90 April 23 0 0 1 23 1 1 23 2024
		(RS) 4	(RS) 4 0 (RS) 4 1	(RS) 4 0 1 0 0	
(RS)	4		1	1 1 0 1	
	4 4	1			1 0 0 0
	4 4	1 1	1		
	4	1 1	1	0 1	
	4		1 1 1		1
	4			-	
4					1

This page is intentionally left blank.

For peer teriew only



PRISMA 2009 Checklist

Page 33 of 33				BMJ Open 36	
1 2	PRTS MA	RISMA 200	09	Checklist ^{mjopen-202}	
3 4 5	Section/topi	ic	#	Checklist item	Reported on page #
6 7	TITLE		on on		
8	Title		1	Identify the report as a systematic review, meta-analysis, or both.	1
9		-	gust		
11 12 13	Structured sur	mmary	2	Provide a structured summary including, as applicable: background; objectives; data source study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
1		ΓΙΟΝ			
16 17 18 19	Rationale		3	Describe the rationale for the review in the context of what is already known.	4
	Objectives		4	Provide an explicit statement of questions being addressed with reference to participants, in error comparisons, outcomes, and study design (PICOS).	4
2	METHODS				
2 22 22 24 25 26 27 28 30 31 32 33 34 35 36 37 38 39 40	Protocol and r	registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	3
	4 Eligibility crite	ria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
	Information sc	ources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
	9 Search 0		8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
	Study selectio	n	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
	4 Data collection	n process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
	Data items		11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
	GRisk of bias in Grudies	individual	12	Describe methods used for assessing risk of bias of individual studies (including specification \vec{B} of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
4	Summary mea	asures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
42 43 44	3 Synthesis of r	esults	14	Describe the methods of handling data and combining results of studies, if done, including results of consistency (e.g., l ²) for each meta-analysis.	5
4				For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 2	
4 4					



PRISMA 2009 Checklist

			BMJ Open 6	Page 34 of 33			
1 2 2	PRISMA 20	009	Checklist mjopen-202				
3 4 5	Section/topic	#	Checklist item	Reported on page #			
6 7 8	Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6			
9 10	Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	5			
11 12	RESULTS	RESULTS					
13 14	Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6			
15 16	Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6			
18	Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	6			
19 20	Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summare data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7/8			
22	Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of sonsistency.	7/8			
23	Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	6			
25	Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8			
26	DISCUSSION						
28 29	Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; congrider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	9			
30 31 32	Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	11			
33	Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10/11			
35	FUNDING		est				
36	Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data), role of funders for the systematic review.	12			
39 40 41 42 43 44 45 46 47	<i>From:</i> Moher D, Liberati A, Tetzlaff doi:10.1371/journal.pmed1000097	J, Altma	an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The RISMA Statement. PLoS Med For more information, visit: <u>www.prisma-statement.org</u> . Page 2 of 2 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	6(7): e1000097.			

BMJ Open

Update on Noma: Systematic review on classification, outcomes and follow-up of patients undergoing reconstructive surgery after Noma disease

Manuscript ID	bmjopen-2020-046303.R1
Article Type:	Original research
Date Submitted by the Author:	30-Jun-2021
Complete List of Authors:	Speiser, Sophie; University College London, Division of Surgery and Interventional Science Langridge, Benjamin; University College London, Division of Surgery and Interventional Science; Royal Free London NHS Foundation Trust, Department of Plastic Surgery Birkl, Moira ; Karl Landsteiner University of Health Sciences Kubiena, Harald; Medical University of Vienna Rodgers, Will; Great Ormond Street Hospital for Children NHS Foundation Trust, Department of Dental and Maxillofacial Surgery
Primary Subject Heading :	Global health
Secondary Subject Heading:	Paediatrics, Surgery, Public health, Dentistry and oral medicine
Keywords:	Nutrition < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, SURGERY, Community child health < PAEDIATRICS, PLASTIC & RECONSTRUCTIVE SURGERY, Paediatric oral & maxillofacial surgery < PAEDIATRIC SURGERY

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievont

Update on Noma: Systematic review on classification, outcomes and follow-up of patients undergoing reconstructive surgery after Noma disease

Authors

Miss Sophie Speiser^{a,b*}, M.D.

Division of Surgery & Interventional Science, University College London, London, United Kingdom

Email: sophie.speiser.19@ucl.ac.uk

Mr Benjamin Langridge^{a,b,c} MRCS Department of Plastic Surgery, Royal Free Hospital, London, United Kingdom Email: <u>b.langridge1@nhs.net</u>

Miss Moira Melina Birkl^d BSc Karl Landsteiner University of Health Sciences, Krems, Austria Email: 01248156@edu.kl.ac.at

Mr Harald Kubiena, M.D.

Private Practice Dr. Kubiena, Vienna, Austria

Email: office@drkubiena.at

Mr Will Rodgers MRCS

Great Ormond Street Hospital for Children NHS Foundation Trust | GOSH · Department of Dental and Maxillofacial Surgery, London, United Kingdom

Email: mr.w.rodgers@gmail.com

Affiliated departments and institutions:

^aDivision of Surgery & Interventional Science, University College London, London, United Kingdom

^bCharles Wolfson Center for Reconstructive Surgery, Royal Free Hospital, London, United Kingdom

^cDepartment of Plastic Surgery, Royal Free Hospital, London, United Kingdom

^dKarl Landsteiner University of Health Sciences, Krems, Austria

Corresponding Author:

Sophie Speiser, M.D.

Sophie.speiser.19@ucl.ac.uk

Phone: +447539539016

Permanent Address:

Division of Surgery & Interventional Science, University College London, London, United Kingdom

Royal Free Hospital, 9th Floor (East), 2QG, 10 Pond St, London NW3 2PS, United Kingdom

Word Count: 3775

ABSTRACT

Introduction: Noma is a significant yet neglected disease which affects some of the least developed countries in the world. The long-term benefit and safety of NOMA surgical reconstructive missions have recently been under scrutiny due to a perceived lack of measurable outcomes and appropriate follow-up. This study analyses and reports on classifications, outcome measurement tools, and follow-up for reconstructive surgery after Noma disease.

Methods: This systematic review was undertaken following PRISMA guidelines. The three medical databases Medline, EMBASE, and Web of Sciences were searched, articles published between 1st of January 1983-15th of April 2020 were included.. All primary evidence on reconstructive surgery following Noma disease, reporting data on outcome after surgery, follow-up time and complications were included. Extracted data were aggregated to generate overall and population corrected mean outcomes and complication rates.

Results: Out of 1,393 identified records, 31 studies including 1,110 Noma patients were analysed. NOITULP and Montandon/WHO were the most commonly used classification systems. Mouth opening and complication rates were the two most often reported outcomes. Overall mean complication rate was 44%, reported by 24 studies. Postoperative mouth opening ("MO") was reported by 8 publications, of which, five reported long-term outcomes (> 12 months). Mean mouth opening improved by 20 mm when compared to mean population weighted preoperative MO (7 mm). At long-term follow-up MO decreased to 20 mm.

Conclusions: Studies reporting on neglected diseases in developing countries often lack methodological rigor. Surgeons should be mindful during patient examination by using a classification system that allows to compare pre- versus postoperative state of disease. Short-term mission surgery is a vital part of healthcare delivery to underdeveloped and poor regions. Future missions should aim at sustainable partnerships with local healthcare providers to ensure postoperative care and long-term patient-oriented follow-up. A shift towards a diagonal treatment delivery approach, whereby local surgeons and healthcare staff are educated and empowered, should be actively promoted.

PROSPERO registration number: CRD42020181931

Keywords: "Noma", "cancrum oris", "ulcerative necrotizing gingivitis", "facial reconstructive surgery", "global developmental surgery", "mission surgery", "classification", "outcomes", "complications", "trismus", "follow-up"

Strengths and limitations of this study

- Our statistical approach (qualitative synthesis) allowed us to compare different outcome measurement methods and give a recommendation for use of classification systems.
- Evidence on surgical methods, outcome and follow-up after Noma disease is scarce and of low quality, which limits the strength of this systematic review.
- The majority of the studies included in this systematic review were case series, which are considered low-quality evidence and therefore limit the generalisability of the results.

- The publications we found represent only a small part of reconstructive surgical missions conducted for Noma disease, which could lead to potential bias of the results.
 - Substantial heterogeneity between studies, including differences in outcome measurement and follow-up, limited our ability to draw clear conclusions about how safe reconstructive missions for Noma surgery are.

to peer terien only

1 INTRODUCTION

Noma is a gangrenous ulcerating bacterial disease of multifactorial origin, mostly prevalent in sub-saharan Africa. Due to the high reported mortality rate of up to 85-90%, and its frequent occurrence in regions of extreme poverty, the WHO officially declared Noma a public health problem in 1994.(1) The global incidence is reported as 30,000-140,000 new cases per year.(1, 2) There are currently 210,000 Noma survivors worldwide, according to latest estimates.(2)

Most cases of Noma occur between the ages of 2-7 years old. Malnutrition, poor oral hygiene and poverty are known etiological factors leading to nutritionally acquired immune deficiency syndrome.(3, 4) Children with this syndrome present with lymphatic atrophy and impaired cellular immune responses, as accompanied by increased vulnerability to infections.(5) These preconditions lead to pathogen invasion through the gingival mucosa.(6, 7) After opportunistic infections take hold, progression to Noma disease occurs in several stages, starting with a simple gingivitis and ending in sequelae such as trismus, feeding difficulties and facial disfigurement.(1) Surgical reconstructive missions have become an established method to reduce the impact of diseases like Noma. The long-term patient benefit of these missions has come under scrutiny on multiple occasions, most recently by Hendriks et al. in 2019.(8)

The purpose of this systematic review is to analyse the currently used classification systems and compare methods of outcome assessment. In addition, the safety and patient-benefit of these procedures are analysed through comparison of complication rates and long-term outcomes.

2 METHODS

A comprehensive, structured literature search of published articles was conducted. This was designed by the authors S.S. and W.R. and performed in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).(9) Methods are described in more detail in the following sections.

2.1 Data sources

The literature search was performed using the electronic databases MEDLINE (PubMed), EMBASE and Web of Science, including articles published between 1st of January 1983-15th of April 2020. The keywords used in the search were selected from key papers and can be found in *Supplementary material- Part A*. Search strings 1 and 2 were combined using the Boolean term AND, then the limits were applied. In addition, a 'MeSH term' search was conducted, and the reference lists of included articles were reviewed for any additional articles.

2.2 Study eligibility criteria

Articles were eligible for inclusion if they provided primary empirical evidence of patient outcomes after Noma surgery. The full inclusion and exclusion criteria are detailed in *Supplementary material- Part A*. Articles were eligible in German and English language. Study selection was independently assessed by 2 reviewers (S.S. and M.B.).

2.3 Data extraction and analysis

Articles were systematically analysed and data extracted using a structured data collection sheet. This data collection template was pilot tested on two selected articles, before being used to assess all included articles. Data extracted included patient demographics (gender, age, comorbidities), and any outcome measurement tools used.

2.4 Methodological quality and assessment of bias

Included studies were assigned a level of evidence based on the Oxford Centre for Evidence Based Medicine.(10) In Addition, studies were rated for methodological quality using the methodological index for non-randomized studies (MINORS) criteria, both tools are explained in detail in *Supplementary material- Part B.*(11)

2.5 Statistical analysis

Data were analysed using IBM SPSS statistics version 24. Descriptive statistics were performed where possible to allow for narrative synthesis. Weighted population mean outcomes were calculated for outcomes of interest.

Meaningful meta-analysis was not possible due to Heterogenous study design and outcome reporting. Averages were represented as a mean and range for normally distributed data and median with IQR for non-normally disributed data. Outcomes were weighted for size of study population, as some studies had larger population sizes and therefore higher weighting.

2.6 Patient and public involvement

Neither patients nor the public were involved in this research.

to beet eview only

3 RESULTS

3.1 Selection of Studies

In total, the systematic literature search identified 1,393 records. In addition, 7 records were identified through bibliography review. After excluding duplicates; titles and abstracts of 1,113 articles were screened, with 1,049 being excluded. Sixty-four studies were fully assessed for eligibility according to the criteria previously established. Thirty-three articles were excluded, 23 of which did not report any outcomes of surgery and 6 had duplicate study populations.

Data were extracted from the 31 included articles. Data extraction was pilot tested on two studies and then performed by two independent reviewers (M.B. and S.S), using a data extraction sheet designed a priori. The selection process was performed according to the PRISMA flow chart, as seen in *Supplementary material- Part C*.

3.2 Details of the Studies

In total, data were available for articles published in the period from 1st of January 1983-15th of April 2020. The methodology, diagnostic approach and surgical treatment varied significantly between the studies. In total, published data for 1,244 patients from 31 studies were analysed, out of which 1,110 patients had reconstructive surgery for Noma disease. In cases of mixed disease populations, estimates were made based on population overall descriptive statistics, dividing the total outcome by Noma population proportions. Patient populations ranged from 2 to 148 patients, with an average of 36 Noma patients enrolled per study. Twenty-nine studies were case series, four of them were prospective,(12-15) 25 were retrospective. Two publications had at least two cohorts,(16-18) two were retrospective cohort studies, and one was a prospectively designed cohort study.(17)

The overall quality of the studies was low. Three publications (16-19) were graded with an evidence Level III according to the Oxford CEBM. The remaining 28 studies were retrospective case series graded as Level IV. The MINORS criteria(11) were used to rate quality of methods of the included studies. The overall MINORS scores ranged from 1 to 8 points, as seen in *Supplementary material- Part D*. Proportional scores were calculated as a percentage of the maximum score of 8 for case series and 12 for cohort studies. Scores ranged from 13-75% of the maximum amount of points. The quality level was generally low: more than half of the studies did not even reach 50% of the ideal outcome.

3.3 Patient Characteristics

Median age for operation was 17 years, reported by 23 studies and ranged from 4.5-35.7 years. 584 (53%) female and 424 (38%) male patients were included. For 102 (9%) patients the gender was not known. The median percentage of female population was 56% (43-65%).

6 studies had a malnutrition rate ranging from 25-100%, with an average of over 56% (median (IQR)) (53.5 (25-81%)) of patients being severely malnourished upon study inclusion. No specific details were given on how malnutrition was measured in the included studies. HIV status was stated by six studies, of which 5 pre-screened patients, and only included HIV seronegative patients.(16, 20-23)

3.4 Classification Systems

The two most common classification systems were the NOITULP, introduced by Marck et al.(15) and the Montandon/WHO, first described by Montandon et al.(24) in 1991, as seen in *Figure 1*.

The NOITULP approach uses the letters N-"nose", O-"outer cheek", I-"inner cheek", T-"trismus", U-"upper lip", L-"lower lip" and P-"particularities" to describe the anatomical subunits affected and gives them a rating from 0-4, depending on the severity of the defect. Nose, cheek, lip and maxilla/mandible involvement were the most commonly mentioned fields, as seen in *Figure 2*.

Six of the included studies used the Montandon classification to rate disease severity. (14, 25-29) Type I represents a localized lip, commissure, or cheek defect that normally can be lined by local tissues and covered with a single flap. Type II includes an upper lip and nose amputation. Type III involves a lower lip and mandible amputation, and Type IV marks large defects involving the lips, cheek, palate, maxillary bone, orbital floor and other entities.

Montandon classification data was available on 376 patients. Out of these, 147 (39%) patients were classified as Montandon Type I, 53 (14%) presented as Montandon Type II, 15 (4%) were rated as Montandon Type III, and 161 (43%) patients had Montandon Type IV.

Trismus as a complication of Noma disease was stated by 26 studies. On average, 59.6% (39.2-95.9) of the patient population per study presented with trismus. Trismus was further subdivided into T1-T4 in 257 patients, as seen in *Figure 3*.

The mean preoperative mouth opening was calculated only for the 257 patients that further divided the trismus classifications into T1-T4. the population weight corrected mean was used as a proxy for comparison where average values were not provided by the original publication. Population weight-corrected median preoperative mouth opening was 7 mm (5-15 mm).

3.5 Surgical Interventions

Hospital duration ranged from 2-140 days, with a mean of 5.5 days. Two hundred and fiftyfive patients were treated by local surgeons in six studies (23%) and 855 patients were operated on by mission surgeons in 20 of the studies (77%).

3.6 Outcomes and Follow-up Time

Objective outcomes were further subdivided into two categories, trismus (MO) and complication rate.

Complication rate as outcome

In total, 204 complications were reported in 24 studies. Median complication rate was 24% (13-53%) per study and ranged between 1%-200%. The 200% complication rate was seen in a study by Hartman et al.(30), where six complications occurred in three patients.

Complication	Rate n (%)
Infection	37 (18)
Partial flap necrosis	26 (13)
Total flap loss and necrosis	20 (10)
Bleeding/hematoma	12 (6)
Donor site dehiscence	12 (6)
Recurrent fistula	11 (5)

Systematic review on Noma surgery

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1	
2	
2 3 4	
4	
5	
6 7 8 9 10	
7	
8	
9	
10	
11	
12	
13	
14	
11 12 13 14 15	
16	
17 18	
18	
19	
20	
21	
22	
19 20 21 22 23 24 25	
24	
25	
26 27	
27	
27 28 29	
29 30	
30 21	
31 32	
32 33	
33 34	
35	
35 36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	

Others

20 (10)

The most common short-term complications can be seen in *Table 1*. Long term complications over 12 months were only stated in two publications. Bisseling et al.(31) reported on long-term results of 36 patients undergoing trismus release with mean follow up of 43 months (12-78). 22% of these patients experienced difficulties eating and 14% had difficulties with speaking. Honeyman et al.(16) reported 15 long term complications: chronic fistula (n=6) chronic infection (n=3) , chronic pain (n=2), keloid scarring (n=2), wound breakdown (n=1), exposed metal work (n=1). In total, 30% of the population (21 patients) experienced long-term complications.

Trismus (mouth opening) as outcome

Trismus release, stated as a postoperative mouth opening (MO) of >3 cm, was achieved in 189 out of 349 patients, reported by 13 publications. Average rate of successful trismus release was 53%. Three publications reported a 100% postoperative trismus release rate.(23, 29, 32) Persisting trismus after surgery was reported in eight publications and was present in 83 out of 286 cases (29%).

Mean postoperative MO was reported only by 8 publications and ranged from 23-35 mm. Population- weighted mean postoperative MO was 27 mm.(24-27)

Mean MO at long-term follow up was available for 5 publications and ranged from 10.3-35.0 mm. Population weighted mean mouth opening at long-term follow up was 20 mm (median (IQR)) (19 (15-21)). *Figure 4* shows population weighted mean mouth opening preoperatively, postoperatively and at long-term follow-up.

Subjective Outcome Measures

Subjective postoperative outcomes included cosmetic/aesthetic improvement, reported by 3 studies, and overall improvement (aesthetic and functional), reported by 8 publications. No further details on how improvement was measured was given by the publishers. No information on if this was patient-measured or observer-measured was stated.

Median length of follow up was reported by only 8 publications, which was 24 months (12.7-45). and ranged from 31 days to 324 months (27 years).(28) Death was reported in 23 cases (2%).(25, 33) Nath and Jovic reported on 81 patients treated on Noma which were HIV positive in Zambia, out of which 11 patients died during initial medical treatment for infection, and 12 (13.6%) died following minor surgery. No further information on comorbidities or health status of these children was provided. In the study published by Chidzonga and Mahova, all patients were HIV seropositive. One patient developed severe pneumonia and died before reconstructive surgery, another patient died one month after admission, no further detail on the cause of death was given. A third patient died one month after initial soft tissue debridement and sequestrectomy. All patients showed severe facial tissue loss and dentoalveolar necrosis.

Long-term follow-up, which was defined as longer than 12 months, was reported by only six publications (263 patients in total), and mean loss to follow-up was 56%.

4 DISCUSSION

Noma affects mostly children in the poorest and least developed regions of the world. It causes facial disfigurement and can lead to functional impariment such as loss of oral competency including salivary leakage and trismus. This is the first systematic review specifically analysing the classification, complications and long-term outcomes of Noma surgery, both in local and in mission surgery settings.

Thirty-one studies met the inclusion criteria, with a total of 1,110 patients included which had undergone reconstructive surgery for Noma disease. The overall methodological quality of the studies, rated by the MINORS criteria, was poor and reflects similar outcomes of the systematic review on trismus conducted by Bouman et al. in 2016 (34). Over half the studies we included reached 50% or less in the MINORS score. Non-randomized studies with high quality are usually rated 83% and higher, according to Slim et al..(11) Out of the 31 studies included, four of them were prospective, and two of them cohort studies.

The methodological limitations of this study include the low-quality evidence of articles and heterogeneity between studies. This led to the lack of data stratification towards parameters such as age, first surgery versus revision surgery and type of defect.

Challenges of performing rigorous studies in the developing world include limited resources and the short time frame of two to three weeks, which the surgeons typically spend on surgical missions. This can be improved by promoting a system where high-quality research can be provided by local staff with the support of plastic surgeons from more developed countries, advocating an academically profitable partnership, sustainable throughout the year.

Classification systems have been proposed by several authors, the two most commonly used were NOITULP, introduced by Marck et al.(15) in 1998 and Montandon/WHO, first described by Montandon et al.(24) in 1991.

Montandon et al.(24) based their system on two publications by Raynaud et al. (35) in 1978 and Cariou (36) in 1986. The approach Montandon suggested was rating the defect based upon its severity, taking into account the surgical strategy needed to successfully reconstruct the face.

Marck et al. found that the previously described classifications lacked in brevity as in conciseness and were not quantifiable in the way NOITULP is.(15) NOITULP covers anatomical subunits and severity of defect, not previously taken into account by any system.

While the Montandon classification has been validated by the WHO in 1994,(1) Noma surgeons are still using both classification systems in parallel. While the Montandon classification is simple and easy to comprehend and apply, it might not fully grasp the disease severity, and it misses one important disease characteristic: trismus. However, the NOITULP classification has a more holistic approach and is more complex in its entirety. The question to be asked is, what do the surgeons want to achieve by using the tool and how can we compare the pre- to postoperative state of the patients and ideally use it as a control system for disease relapse or progression in trismus patients. In addition, the system must be comprehensible by the surgeon using it, which ultimately shall be a surgeon within the local healthcare system. One suggestion might be to distinguish between a role for a more complex classification to be used predominantly in the research setting, while the other could have a more direct clinical role. In addition, the role of patient reported outcome measures (PROMs) should be explored with Noma patients for pre- and postoperative evaluation. If the patient does feel that they have benefited from the operation, this may be more relevant than the surgeons' report or the classification system. Validated questionnaires are one possible way

to report patient-reported outcomes.(37) They are essential for pre- and postoperative interviews and evaluation of the patients view on benefit from the operation.

Out of the 31 studies analysed, in only six studies were the operations undertaken by a local surgeon. The majority of operations were undertaken by mission surgeons travelling to the region. This vertical approach to healthcare includes short missions of two to three weeks. Unfortunately, these missions are typically characterised by a higher risk of poor follow up. They are also often fail to provide a holistic approach to the patient's ongoing treatment after surgery, especially when compared against clinics that include permanent local surgeons and healthcare staff.(8) This was well reflected in the outcomes and follow up seen in the 31 publications we analysed. Outcome measurements were inconsistent, and follow-up was incomplete in the majority of publications (81%).

While postoperative complication rates were available for the majority of studies (77%), long term complications were only reported by two publications. Bisseling et al.(31) reported that 22% of patients experienced loss of oral competency and 14% had difficulties with speaking. Honeyman et al. reported a 30% long-term complication rate. These high long-term complication rates, including severe complications such as loss of oral competency, make the long-term benefit of these short-term missions questionable, as stated previously by Hendriks et al. (8) Reasons for the high complication rates could be lack of postoperative physiotherapy and/or regular follow-up visits. It is therefore important that any surgical missions develop links with the local healthcare system in order to ensure that complications can be managed effectively and to provide training where required for local healthcare workers.

Postoperative mouth opening as an outcome of trismus release was reported by eight studies, and long-term follow up data were available for five publications. Underreporting of outcomes and limited follow-up Underreporting of outcomes and lack of follow-up could lead to underestimation or overestimation of benefits to the patients. Nevertheless, population-corrected mean postoperative mouth opening at long-term follow up (>12 months) was 20 mm, which represents a 13 mm increase compared to the preoperative mean. It is worth mentioning at this point, that there is broad range of ages for the patients included in this review. Whether a 20 mm increase in mouth opening is of any relevance changes based on age as an adult mouth is larger than a young child's mouth. Unfortunately, no further details were given on the ages of the patients measured at long-term follow up. Also, most cases of Noma occur between the ages of 2-7 years old, and the median age of the reconstruction was 17 years (range from 4.5-35.7), so the long term evolution may influence the outcome.

Bisseling et al.(31) followed-up patients treated in the Noma Childrens Hospital in Sokoto, Nigeria. In this mission hospital, in the majority of patients, contact is lost entirely after discharge and long-term outcome is not known. Therefore, they tried to revisit the patients in their home communities to retrieve patient outcome data. Out of 130 patients documented, only 36 patients were found and included into the study, representing a greater than 70% loss to follow-up rate. Similarly high losses were reported by Pittet et al. (79%) and Vinzenz et al. (38) (78%) and slightly less by Dammer et al. (50%), reflecting the challenges of providing adequate ongoing care in the developing world. Reasons for high losses to follow-up could be inconsistency in local healthcare provision and lack of infrastructure and long distances that have to be overcome by the parents and the child to reach the local clinics.

Ruegg et al. (27) lost only 21% of their patients to follow-up, with their patients being treated in Switzerland and repatriated following discharge from hospital. They were followed up by the local healthcare workers of the Swiss charity Sentinelles. They implemented a local complication report and follow up system, working together with physiotherapists and ensuring local healthcare support and regular controls throughout the year. Whereas it is often not feasible to fly Noma patients to Europe for treatment, their strategy of consistent local care and staff to oversee the postoperative healing process on site helped them stay connected with their patients and ensured their wellbeing after reintegration.

Transition from a vertical approach, where short-term missions are performed, but no activities throughout the year are supported, to a more diagonal strategy, used for mission surgery in underdeveloped countries, has previously been suggested by Patel et al. (39). In this model, which was originally developed for cleft lip and palate patients, they combine short-term missions with ongoing measures such as the support of local staff with residency programs, financial support, research training, academic partnerships and equipment for surgery.

This sustainable treatment strategy was further promoted by Hendriks et al. (8) in 2019. Working together with local staff and implementing a mutually beneficial partnership helps ensure a holistic approach towards healthcare provision and management in underdeveloped countries.

Advantages of this system include development of a long-term presence in the respective countries with the ultimate goal of building local surgical capacity and treatment independence in a supported setting. Visiting surgeons benefit from experience in global healthcare delivery and have the chance to transfer their knowledge to local surgeons, who gain surgical skills and experience. In addition, other local healthcare workers can be trained including nutritionists, physiotherapists and speech therapists, to support the patients in the perioperative settings (39).

Data on how far this has been implemented in hospitals treating Noma patients is scarce. However, given the low long-term follow-up rate and incomplete reporting of outcomes in studies published up to date, implementation of this model is likely limited in Noma patients.

The diagonal treatment strategy combined with a patient-centered outcome evaluation system including PROM's in the form of validated and standardized questionnaires could lead to a sustainable, patient-centered and holistic treatment system for survivors of NOMA disease.

The systematic review conducted demonstrates the current most common classification systems used, outcomes and follow-up for reconstructive surgery following Noma disease to-date. Consistency in classifying and following up on patients imposes a challenge for neglected diseases in developing countries, no less so for Noma. When classifying disease severity of Noma patients, surgeons should aim to achieve comparability of the pre- versus postoperative and long-term status by using a classification system that allows documentation of affected anatomical subunits, as well as to note trismus severity at every point in follow-up.

Tools for measuring surgical outcomes in Noma patients are scarce and need further research and validation. Complication rates and mouth opening were the two most commonly reported outcomes. In general, reported outcomes were often inconsistent and of low quality, as was evidence of follow-up data. Short-term mission surgery is a vital part of healthcare delivery to underdeveloped regions. Future missions should focus on fostering cooperation and forming partnerships with local organisations to ensure postoperative care and long-term patient-oriented follow-up. A shift towards a diagonal treatment delivery approach where local surgeons and healthcare staff are educated and supported should be actively promoted.

Abbreviations:

1	
2 3	CEBM- Center of evidence-based medicine
4	IQR- Interquartile range
5	
6 7	MINORS- Methodological index for non-randomized studies
8	MO- Mouth opening
9 10	NOITULP- anagram as classification system for Noma disease
11 12	PRISMA- Preferred reporting items for systematic reviews and meta-analyses
13	WHO World Health Organization
14	WHO- World Health Organization
15 16	
17	Author Contributions:
18	
19 20	Miss Sophie Speiser, M.D.: First reviewer, design of study, data analysis, data interpretation,
20	manuscript preparation
22	Miss Moira Melina Birkl BSc.: Second reviewer, design of study, data interpretation,
23	manuscript preparation
24	Mr Benjamin Langridge MRCS: Third reviewer, design of study, data interpretation,
25 26	manuscript preparation
27	
28	Mr Harald Kubiena, M.D.: design of study, manuscript preparation
29	Mr Will Rodgers MRCS: design of study, data interpretation, manuscript preparation
30 31	
32	
33	Funding: This work has not previously been presented in any format. This research did not
34	receive any specific grant from funding agencies in the public, commercial, or not-for-profit
35	sectors. The article processing charge was kindly paid for by University College London as
36 37	part of their Open Access policy.
38	
39	Data sharing statement: No additional data available'.
40	Competing interests: None declared.
41 42	
43	Ethics statement: No human participants included/ no animal participants included.
44	
45	
46 47	
47 48	
49	
50	
51	
52 53	
53 54	
55	
56	

BMJ Open

REFERENCES

1. Bourgeois DM, Leclercq MH. The World Health Organization initiative on noma. Oral Dis. 1999;5(2):172-4.

2. Srour ML, Marck K, Baratti-Mayer D. Noma: Overview of a Neglected Disease and Human Rights Violation. Am J Trop Med Hyg. 2017;96(2):268-74.

3. Chandra RK. 1990 McCollum Award lecture. Nutrition and immunity: lessons from the past and new insights into the future. Am J Clin Nutr. 1991;53(5):1087-101.

4. Leila Srour M, Marck KW, Baratti-Mayer D. Noma: neglected, forgotten and a human rights issue. Int Health. 2015;7(3):149-50.

5. Beisel WR. Nutrition and Immune Function: Overview. The Journal of Nutrition. 1996;126(suppl_10):2611S-5S.

6. Baratti-Mayer D, Gayet-Àgeron A, Hugonnet S, Francois P, Pittet-Cuenod B, Huyghe A, et al. Risk factors for noma disease: a 6-year, prospective, matched case-control study in Niger. Lancet Glob Health. 2013;1(2):e87-e96.

7. Baratti-Mayer D, Pittet B, Montandon D, Bolivar I, Bornand JE, Hugonnet S, et al. Noma: an "infectious" disease of unknown aetiology. Lancet Infect Dis. 2003;3(7):419-31.

8. Hendriks TCC, Botman M, Rahmee CNS, Ket JCF, Mullender MG, Gerretsen B, et al. Impact of short-term reconstructive surgical missions: a systematic review. BMJ Global Health. 2019;4(2):e001176.

9. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.

10. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plastic and reconstructive surgery. 2011;128(1):305-10.

11. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712-6.

12. Bouman MA, Marck KW, Griep JE, Marck RE, Huijing MA, Werker PM. Early outcome of noma surgery. J Plast Reconstr Aesthet Surg. 2010;63(12):2052-6.

13. Dammer R, Dunzl B, Kuhnel T. [Therapy of bony and fibrous contractures and buccal defects after noma using the temporalis muscle flap]. Mund Kiefer Gesichtschir. 2005;9(4):225-32.

14. Kuhnel TS, Dammer R, Dunzl B, Beule AG, Strutz J. New split scar cheek flap in reconstruction of noma sequelae. Br J Plast Surg. 2003;56(6):528-33.

3

4 5

6

7

8 9

10

11

13

14

15

16 17

18

19

20 21

23 24

25

26

27

29

31 32

33

35 36

37

39 40

41

42

43 44

45

46

47 48

49

50

51 52

53

54

55 56

57

60

Marck KW, De Bruijn HP, Schmid F, Meixner J, Van Wijhe M, Van 15. Poppelen RHM. Noma: The Sokoto approach. European Journal of Plastic Surgery. 1998;21(6):277-80. Honeyman C, Patel V, Yonis E, Fell M, Demissie Y, Eshete M, et 16. al. Long-term outcomes associated with short-term surgical missions treating complex head and neck disfigurement in Ethiopia: A retrospective cohort study. Journal of Plastic, Reconstructive and 12 Aesthetic Surgery. 2020. Huijing MA, Marck KW, Combes J, Mizen KD, Fourie L, Demisse 17. Y, et al. Facial reconstruction in the developing world: a complicated matter. Br J Oral Maxillofac Surg. 2011;49(4):292-6. 18. Marck R, Huijing M, Vest D, Eshete M, Marck K, McGurk M. Early outcome of facial reconstructive surgery abroad: a comparative study. European journal of plastic surgery. 2010;33(4):193-7. Oluwasanmi JO, Lagundoye SB, Akinyemi OO. Ankylosis of the 19. 22 mandible from cancrum oris. Plast Reconstr Surg. 1976;57(3):342-50. Giessler GA, Borsche A, Lim PK, Schmidt AB, Cornelius CP. First 20. experiences with simultaneous skeletal and soft tissue reconstruction of noma-related facial defects. J Reconstr Microsurg. 2012;28(2):85-94. 28 Giessler GA, Cornelius CP, Suominen S, Borsche A, Fieger AJ, 21. Schmidt AB, et al. Primary and secondary procedures in functional and 30 aesthetic reconstruction of noma-associated complex central facial defects. Plast Reconstr Surg. 2007;120(1):134-43. Giessler GA, Fieger A, Cornelius CP, Schmidt AB. Microsurgical 22. 34 reconstruction of noma-related facial defects with folded free flaps: an overview of 31 cases. Ann Plast Surg. 2005;55(2):132-8. 23. Giessler GA, Schmidt AB. Noma: experiences with а 38 microvascular approach under West African conditions. Plast Reconstr Surg. 2003;112(4):947-54; discussion 55-6. Montandon D, Lehmann C, Chami N. The surgical treatment of 24. noma. Plast Reconstr Surg. 1991;87(1):76-86. Chidzonga MM, Mahomva L. Noma (cancrum oris) in human 25. immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV and AIDS): clinical experience in Zimbabwe. J Oral Maxillofac Surg. 2008;66(3):475-85. 26. Pittet B, Jaquinet A, Montandon D. Clinical experience in the treatment of noma sequelae. J Craniofac Surg. 2001;12(3):273-83. Ruegg EM, Baratti-Mayer D, Jaquinet A, Montandon D, Pittet-27. Cuenod B. The surgical management of extra-articular ankylosis in noma patients. Int J Oral Maxillofac Surg. 2018;47(12):1527-33. 28. Ruegg EM, Gniadek P, Modarressi A, Baratti-Mayer D, Pittet-Cuenod B. Facial bone reconstruction with prefabricated vascularized 58 calvarium flaps in children and young adults: Advantages and long-term 59 results. Journal of Cranio-Maxillofacial Surgery. 2016;44(12):1880-8.

BMJ Open

1 2

3

4 5

6

7

8 9

10

11

12

13

14

15 16

17

18

19

20 21

22

23

24 25

26

27 28

29

30

31 32

33

34

35 36

37

38

39 40

41

42

43 44

45

Page 18 of 33

29. Simon F, Wolfe SA, Guichard B, Bertolus C, Khonsari RH. Paul Tessier facial reconstruction in 1970 Iran, a series of post-noma defects. J Craniomaxillofac Surg. 2015;43(4):503-9. Hartman EHM, Van Damme PA, Sauter H, Suominen SHH. The 30. use of the pedicled supraclavicular flap in noma reconstructive surgery. Journal of Plastic. Reconstructive and Aesthetic Surgery. 2006;59(4):337-42. Bisseling P, Bruhn J, Erdsach T, Ettema AM, Sautter R, Berge SJ. 31. Long-term results of trismus release in noma patients. Int J Oral Maxillofac Surg. 2010;39(9):873-7. 32. Holle J. Lockjaw treatment after noma in the third world. J Craniofac Surg. 2009;20 Suppl 2:1910-2. 33. Nath S, Jovic G. Cancrum oris: management, incidence, and implications of human immunodeficiency virus in Zambia. Plast Reconstr Surg. 1998;102(2):350-7. Bouman MA, Dijkstra PU, Reintsema H, Roodenburg JL, Werker 34. PM. Surgery for extra-articular trismus: a systematic review. Br J Oral Maxillofac Surg. 2016;54(3):253-9. Reynaud J, Garand G, Ployet MJ, Robier A. Du noma au 35. syndrome de Silvermann: une pathogÈnie ± discuter. Ann Chir Plast. 1978;23(4):227-30. 36. Cariou J, editor Le noma dans la corne de l'Afrique: approche thérapeutique. Ann Chir Plast Esthet; 1986. Weldring T, Smith SMS. Patient-Reported Outcomes (PROs) and 37. Patient-Reported Outcome Measures (PROMs). Health Serv Insights. 2013;6:61-8. Vinzenz K, Holle J, Wuringer E. Reconstruction of the maxilla with 38. prefabricated scapular flaps in noma patients. Plast Reconstr Surg. 2008;121(6):1964-73. Patel PB, Hoyler M, Maine R, Hughes CD, Hagander L, Meara JG. 39. An opportunity for diagonal development in global surgery: cleft lip and resource-limited settings. Plast palate care in Surg Int. 2012:2012:892437-.

FIGURES AND TABLES

Table 1- Most common short-term complications 6


Figure 1- Noma classification systems used 6

Figure 2- Subunits used for disease classification 6

Figure 3- Trismus severity reported preoperatively 6


Figure 4- Mouth opening at preoperative, postoperative and long-term follow-up points 7

Page 21 of 33 Noma classific ation systems used




Subunits used for Malerease classification

Page 22 of 33




Page 23 of 33

Trismers Severity



Mean Mowthe Opening

Page 24 of 33



SUPPLEMENTARY MATERIAL

PART A- SEARCH STRATEGY

Keywords

Search strategy for Embase.com (15.04.2020)

/exp = EMtree keyword with explosion

.tw = The Textword field in EMBASE includes Title (TI) and Abstract (AB).

N 7 N			
Number	Search terms	Results	
#1	exp plastic surgery/ OR exp surgeon/ OR exp plastic surgeon/ OR exp esthetic surgery/ OR	8557452	
	exp skin transplantation/ OR exp microsurgery/ OR exp tissue flap/ OR exp Z plasty/ OR exp		
	surgical flaps/ OR exp reconstructive surgery/ OR exp face surgery/ OR exp maxillofacial		
	surgery/ OR exp oral surgery/ OR skin graft*.tw. OR full thickness graft*.tw. OR SSG.tw. or		
	FTG.tw OR axial flap*.tw. OR pedicled flap*.tw. OR surgical flap*.tw. OR contracture		
	release*.tw. OR exp free tissue graft/ OR free flap*.tw. OR regional flap*.tw. OR exp skin		
	flap/ OR local flap*.tw. OR surger*.tw. OR surgical*.tw. OR operation*.tw. OR		
	operative*.tw. OR incisi*.tw. OR excisi*.tw. OR management*.tw. OR treatment.tw		
	6.		
#2	Exp Vincent stomatitis/ OR acute necrotizing ulcerative gingivitis.tw OR acute necrotising	1401	
	ulcerative gingivitis.tw OR acute ulcerative gintivitis.tw OR Noma.tw OR cancrum oris.tw		
#3	#1 AND #2	639	
Limits: Pu	blication prior to final search, April 15th, 2020		

Search strategy for MEDLINE (PubMed) (15.04.2020)

/exp = MEDLINE keyword with explosion/ Mesh terms .tw = The Textword field in MEDLINE includes Title (TI) and Abstract (AB).

Number	Search terms			Results
#1	exp Reconstructive Surgical Procedures/ OR exp Surgery, Plastic/ OR exp Tissue		8167413	
	Transplantation/	OR exp Surgical Flaps/	OR exp Skin Transplantation/ ORexp Free	
	Tissue Flaps/	OR exp Microsurgery/ OR e	xp Surgery, Oral/ OR exp Surgical	
	Procedures, Opera	ocedures, Operative/ OR exp "Oral and Maxillofacial Surgeons"/ OR exp Surgeons/ OR		
	skin graft*.tw.	OR full thickness graft*.tw.	OR SSG.tw. OR FTG.tw. OR axial flap*.tw.	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	OR pedicle flap*.tw. OR pedicled flap*.tw. OR surgical flap*.tw. OR contracture release*.tw. OR free flap*.tw. OR regional flap*.tw. OR local flap*.tw. OR surger*.tw. OR surgical*.tw.	
	OR operation*.tw. OR operative*.tw. OR incisi*.tw. OR excisi*.tw. OR management*.tw.	
	OR treatment*.tw	
#2	exp Noma/ OR cancrum oris.tw. OR exp Gingivitis, Necrotizing Ulcerative/ OR acute	1664
	necrotizing ulcerative gingivitis.tw. OR acute necrotising ulcerative gingivitis.tw.	
#3	#1 AND #2	568
Limits:	Publication prior to final search, April 15th, 2020	
Limits:	Publication prior to final search, April 15th, 2020	

Search strategy for Clarivate Analytics/Web of Science (15.04.2020)

TOPIC = words in title, abstract or keywords ndexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years

Number	Search terms	Results
#1	TS= (surger* OR surgical* OR surgeon* OR operation* OR operative* OR incisi* OR	9,621,445
	extracti* OR excisi* OR management* OR treatment*)	
#2	TS= (reconstructi* OR cosmetic* OR esthetic* OR aesthetic* OR plastic OR corrective* OR	8,095,337
	oral* or *maxillofacial* OR facial OR face* OR "head and neck" OR flap* OR skin* or	
	micro*)	
	4	
#3	TS= (Noma OR "cancrum oris" OR "necrotizing ulcerative gingivitis" OR "acute necrotizing	3,515
	ulcerative gingivitis" OR "acute necrotising ulcerative gingivitis")	
#4	#2 AND #1	1,821,209
#5	#4 AND #3	186
Limits: Pu	blication prior to final search, April 15th, 2020	

Inclusion/exclusion criteria

Inclusion Criteria 1. Original publications 2. Human subjects 3. Case Series, Retrospective Data Analyses, Clinical Trials, Controlled Clinical Trials, Prospective Studies

2	
3	
4	
5	
6 7	
/	
8	
9	
10	
11	
12	
12 13	
14	
14	
15	
16 17	
17	
18	
19	
20	
21	
22	
23	
19 20 21 22 23 24 25 26 27 28 29	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
2/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
47 48	
49	
50	
51	
52	
53	
54	
55	
56	
50 57	
58	
59	
60	

Exclusion Criteria Publication type does not match inclusion criteria (Review articles, Mixed methodology studies without 1. subgroup data, Animal studies, Conference Articles) Conditions other than Noma, Cancrum Oris, or Necrotizing Ulcerative Stomatitis not related to Noma 2. 3. The paper is about conditions located at sites other than the Maxillofacial and Head and Neck region 4. The paper is not about treatment The paper is not about a surgical intervention (but included if terms such as reconstruction or rehabilitation, 5. or flap or graft, are mentioned).

- The paper is about prevention rather than treatment of Noma 6.
- ... 7. The paper is written in a language other than German or English

Systematic review on Noma surgery For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

PART B- MINORS CRITERIA

Level of Evidence	Types of Studies
I	SR (with homogeneity) of RCTs, Individual RCT (with narrow Confidence Interval),
II	SR (with homogeneity) of cohort studies, Individual cohort study (including low quality RCT; e.g., <80% follow-up), "Outcomes" Research; Ecological studie
III	SR (with homogeneity*) of case-control studies, Individual Case-Control Study
IV	Case-series (and poor-quality cohort and case-control studies)
v	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"

MINORS criteria
1. A clearly stated aim: the question addressed should be precise and relevant in the light of available literature
2. Inclusion of consecutive patients: all patients potentially fit for inclusion (satisfying the criteria for inclusion) has
been included in the study during the study period (no exclusion or details about the reasons for exclusion)
3. Prospective collection of data: data were collected according to a protocol established before the beginning of the study
4. Endpoints appropriate to the aim of the study: unambiguous explanation of the criteria used to evaluate the ma outcome which should be in accordance with the question addressed by the study. Also, the endpoints should be assessed
on an intention-to-treat basis.
5. Unbiased assessment of the study endpoint: blind evaluation of objective endpoints and double-blind evaluation subjective endpoints. Otherwise the reasons for not blinding should be stated

6. Follow-up period appropriate to the aim of the study: the follow-up should be sufficiently long to allow the assessment of the main endpoint and possible adverse events

7. Loss to follow up less than 5%: all patients should be included in the follow up. Otherwise, the proportion lost to follow up should not exceed the proportion experiencing the major endpoint

8. Prospective calculation of the study size: information of the size of detectable difference of interest with a calculation of 95% confidence interval, according to the expected incidence of the outcome event, and information about the level for statistical significance and estimates of power when comparing the outcomes

Additional criteria in the case of comparative study

9. An adequate control group: having a gold standard diagnostic test or therapeutic intervention recognized as the optimal intervention according to the available published data


10. Contemporary groups: control and studied group should be managed during the same time period (no historical comparison)

11. Baseline equivalence of groups: the groups should be similar regarding the criteria other than the studied endpoints. Absence of confounding factors that could bias the interpretation of the results

12. Adequate statistical analyses: whether the statistics were in accordance with the type of study with calculation of confidence intervals or relative risk

tor peer teriew only

PART C- PRISMA FLOW CHART



PART D- MINORS CRITERIA FOR INCLUDED STUDIES

Adams-ray Adekeye Adekeye Bisseling Bouman Chidzonga Dammer Erdmann Giessler Giessler Giessler Giessler Giessler Hartman Heitland Holle Holle J.	1992 1983 1986 2010 2008 2005 1998 2003 2005 2007 2011 2006 2004	Type case series (RS) case series (RS)		1 2 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1	l 0 l 0	$\begin{array}{cccc} 1 & 0 \\ 1 & 0 \\ 1 & 0 \\ 1 & 1 \\ 1 & 0 \\ 0 & 0 \\ 1 & 0 \\ 0 & 0 \\ 0 & 0 \end{array}$	0 0 1 1 0 1 0	$ \begin{array}{c} 1 \\ 0 \\ 1 \\ 0 \\ 1 \\ 0 \\ $	െ െ മായ് പ്രത്യാണ്ണന്നുന്നു. പ്രത്യാന് പ്രത്യാന് പ്രത്യാന് പ്രത്യാന് പ്രത്യാന്ന്നം പ്രത്യാന്നം പ്രത്യാന് പ്രത്യാന് പ			12	Total 4 3 3 6 6 6
Adekeye Bisseling Bouman Chidzonga Dammer Erdmann Giessler Giessler Giessler Giessler Hartman Heitland Holle	1986 2010 2008 2005 1998 2003 2005 2007 2011 2006 2004	case series (RS) case series (RS) case series (PS) case series (RS) case series (RS)		1 0 1 1 1 1 1 1 1 1 1 1 0 1 1 1 0 1 0	0 0 1 0 1 1 1 1 1 1 1 0	$\begin{array}{cccc} 1 & 0 \\ 1 & 1 \\ 1 & 0 \\ 0 & 0 \\ 1 & 0 \\ 0 & 0 \end{array}$	0 1 1 0 1	1 0 1 0 0	gust <u>2</u> 021 චල				3 6 6
Bisseling Bouman Chidzonga Dammer Erdmann Giessler Giessler Giessler Giessler Hartman Heitland Holle	2010 2010 2008 2005 1998 2003 2005 2007 2011 2006 2004	case series (RS) case series (PS) case series (RS) case series (RS)		1 1 1 1 1 1 1 1 0 1 1 1 0 1 1 1 0 1	1 0 1 1 1 0 1 1 1 1 1 1	$\begin{array}{cccc} 1 & 1 \\ 1 & 0 \\ 0 & 0 \\ 1 & 0 \\ 0 & 0 \end{array}$	1 1 0 1	1 0 0	<u>ෂ් 202</u> .ටල				6 6
Bouman Chidzonga Dammer Erdmann Giessler Giessler Giessler Giessler Hartman Heitland Holle	2010 2008 2005 1998 2003 2005 2007 2011 2006 2004	case series (PS) case series (RS) case series (RS)		с .	l 1 l 0 l 1 l 1 l 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1 0 1	1 0 0	2021.De				6
Chidzonga Dammer Erdmann Giessler Giessler Giessler Giessler Hartman Heitland Holle	2008 2005 1998 2003 2005 2007 2011 2006 2004	case series (RS) case series (PS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS)		с .	l 0 l 1 l 1 l 0	$\begin{array}{ccc} 0 & 0 \\ 1 & 0 \\ 0 & 0 \end{array}$	0 1	0	21-De				
Dammer Erdmann Giessler Giessler Giessler Giessler Hartman Heitland Holle	2005 1998 2003 2005 2007 2011 2006 2004	case series (PS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS)		с .	l 1 l 1 l 0	$\begin{matrix} 1 & 0 \\ 0 & 0 \end{matrix}$	1	0	Ю С				2
Erdmann Giessler Giessler Giessler Giessler Hartman Heitland Holle	1998 2003 2005 2007 2011 2006 2004	case series (RS) case series (RS) case series (RS) case series (RS) case series (RS) case series (RS)		с .		0 0	1		(P				2
Giessler Giessler Giessler Hartman Heitland Holle	2003 2005 2007 2011 2006 2004	case series (RS) case series (RS) case series (RS) case series (RS) case series (RS)		с .			0		°≶				5
Giessler Giessler Hartman Heitland Holle	2005 2007 2011 2006 2004	case series (RS) case series (RS) case series (RS) case series (RS)		с .		0 0		0	ola				3
Giessler Giessler Hartman Heitland Holle	2007 2011 2006 2004	case series (RS) case series (RS) case series (RS)		с .			1	0	ba ba				2
Giessler Hartman Heitland Holle	2011 2006 2004	case series (RS) case series (RS)	4 4	с .		0 0	0	0	ୁ ଜ୍				2
Hartman Heitland Holle	2006 2004	case series (RS)	4			0 0	0	0	μ <u></u>				1
Heitland Holle	2004			1 (0 0	0	0	ĥ				1
Holle		· (DC)	4	1 () 0	$ \begin{array}{ccc} 0 & 0 \\ 1 & 0 \end{array} $	0	0	0 L				1
	2020	case series (RS) case series (RS)	4	1 1		1 0	0	0	ц.				4
none J.	2020 2009	case series (RS)	4		10 10	1 1	1	0	Jo				5 6
Honeyman	2009	cohort study (RS)	4			1 1	1	1		0	0	1	8
Huijing	2019	cohort study (PS)	3		1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1	0			0	1	6
Kuehnel	2003	case series (PS)	4	1	1		1	1	с С С	0	0	1	5
Marck	1998	case series (PS)	4	0	1	0 0	0	0	ã.				2
Montandon	1991	case series (RS)	4	0	0	0 0	0	0	0B				1
Nath	1997	case series (RS)	4	1 1		1 1	1	1	R				6
Oluwasanmi	1976	case series (RS)	4	1 1	1	1 0	0	1	08				5
Pittet	2001	case series (RS)	4	1 1	1	0 0	1	1	0				5
Rodgers	2015	case series (RS)	4	1 1	l 1	1 0	0	0	₫ <u>0</u>	0	0	0	4
Rüegg	2016	case series (RS)	4	1 1	0	1 0	1	1	2				5
Ruegg	2018	case series (RS)	4	1 1	0	1 0	1	1	Q)				5
Saleh	2013	case series (RS)	4	1 1	l 1	1 0	0	0	02				4
Shaye	2018	case series (RS)	4	1 1	0	0 0	0	0	40				2
Simon	2015	case series (RS)	4	1 1	1	1 0	0	0	ං හ April 23 _ට 2024 by භූම				4
Vinzenz	2008	case series (RS)	4	1 1	l 0	1 0	1	1	ଳି				5
									est				
									Р				
									of				
									ec				
									te				
									d b				
									Protected by copyrigh				
									cop				

This page is intentionally left blank.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



PRISMA 2009 Checklist

Page 33 of 33				BMJ Open 36	
1 2	PRTS MA	RISMA 200	Checklist ^{mjopen-202}		
3 4 5	Section/topi	ic	#	Checklist item	Reported on page #
6 7	TITLE		on on		
8	Title		1	Identify the report as a systematic review, meta-analysis, or both.	1
9		-	gust		
1 12 12	Structured sur	mmary	2	Provide a structured summary including, as applicable: background; objectives; data source study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
1		ΓΙΟΝ			
1	Rationale		3	Describe the rationale for the review in the context of what is already known.	4
1 1 1	Objectives		4	Provide an explicit statement of questions being addressed with reference to participants, in error comparisons, outcomes, and study design (PICOS).	4
2	METHODS				
2	Protocol and r	registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	3
24 25	4 Eligibility crite	ria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
2	Information sc	ources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
29	9 Search 0		8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
3	Study selectio	n	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
3	4 Data collection	n process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
3	Data items		11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
3 3 4	GRisk of bias in Grudies	individual	12	Describe methods used for assessing risk of bias of individual studies (including specification \vec{B} of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
4	Summary mea	asures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
4 4 4	3 Synthesis of r	esults	14	Describe the methods of handling data and combining results of studies, if done, including results of consistency (e.g., l ²) for each meta-analysis.	5
4				For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 2	
4 4					



PRISMA 2009 Checklist

			BMJ Open 6	Page 34 of 33
1 2 2	PRISMA 20	009	Checklist mjopen-202	
3 4 5	Section/topic	#	Checklist item	Reported on page #
6 7 8	Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
9 10	Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	5
11 12	RESULTS	-	021	
13 14	Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
15 16	Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6
18	Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	6
19 20	Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summare data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7/8
22	Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of sonsistency.	7/8
23	Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	6
25	Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8
26	DISCUSSION	<u> </u>		
28 29	Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; congrider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	9
30 31 32	Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	11
33	Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10/11
35	FUNDING	<u>.</u>	est	
36	Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data), role of funders for the systematic review.	12
39 40 41 42 43 44 45 46 47	<i>From:</i> Moher D, Liberati A, Tetzlaff doi:10.1371/journal.pmed1000097	J, Altma	an DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The RISMA Statement. PLoS Med For more information, visit: <u>www.prisma-statement.org</u> . Page 2 of 2 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	6(7): e1000097.